*Please note that this translation is to be used solely as reference.
In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.
Supplementary Information of Consolidated Financial Results
for the Nine Months ended December 31, 2025
Feb 13, 2026
Linical Co., Ltd.
Consolidated Financial Results
Units: Millions of yen, % | Results for the Nine Months Ended December 31, 2024 | Results for the Nine Months Ended December 31, 2025 | |||
Amount | Net Sales | Amount | Net Sales | Year-on-Year | |
Net Sales | 7,955 | 100.0 | 6,837 | 100.0% | △14.0 |
Cost of Sales | 6,097 | 76.6 | 5,726 | 83.8% | △6.1 |
SG&A Expenses | 2,189 | 27.5 | 2,388 | 34.9% | 9.1 |
Operating Profit | △332 | △4.2 | △1,277 | △18.7% | - |
Ordinary Profit | △261 | △3.3 | △1,233 | △18.0% | - |
Net Profit | △316 | △4.0 | △1,551 | △22.7% | - |
Net Sales
Net sales increased year-on-year in Japan, Europe, Taiwan and China due to change orders for existing projects and acquisition of new projects, but decreased on a consolidated basis due to
decreased sales in the US and
South Korea.
Operating Profit
Positive operating income in Taiwan and China, and operating loss decreased in Japan, but operating loss increased on a consolidated basis due to significant impact of operating loss in the US and Europe.
Financial Results by Region
Unit: Millions of yen | Results for the Nine Months Ended December 31, 2024 | Results for the Nine Months Ended December 31, 2025 | |||||||
Net Sales ** | Operating Profit | Ordinary Profit | Net Sales ** | Rate of Change % | Operating Profit | Rate of Change % | Ordinary Profit | Rate of Change % | |
Japan | 2,794 | △374 | △346 | 2,958 | 5.9 | △305 | - | △179 | - |
United States | 3,603 | 543 | 575 | 2,407 | △33.2 | △348 | - | △327 | - |
Europe | 2,334 | △63 | △101 | 2,424 | 3.8 | △316 | - | △394 | - |
Korea | 544 | △91 | △37 | 489 | △10.1 | △90 | - | △110 | - |
Taiwan | 58 | △37 | △36 | 151 | 160.5 | 17 | - | 15 | - |
China | 155 | 1 | △1 | 194 | 24.6 | 44 | 3,728.4 | 40 | - |
Consolidation Adjustments* | △1,535 | △309 | △313 | △1,788 | - | △278 | - | △277 | - |
Total | 7,955 | △332 | △261 | 6,837 | △14.0 | △1,277 | - | △1,233 | - |
Financial Results by Region
Japan:
Sales increased and operating loss narrowed due to multiple new projects awarded from pharmaceutical companies in Japan and overseas.
Aim to improve performance through initiatives to raise personnel utilization and rigorous expense control.
US:
Sales decreased due to inability to compensate for decreased sales resulting from completion of large-scale projects, resulting in operating loss.
Despite unofficial acceptance of orders for several large-scale global clinical trials, these did not contribute to sales because the government shutdown delayed the start of trials.
Europe:
Revenues increased due to change orders for existing projects that extended the duration of existing projects and added man-hours.
Operating loss expanded due to an increase in outsourcing costs and other expenses.
Asia:
Korea: Substantial decrease in revenue due to suspension of multiple projects for customer reasons, but slight decrease in operating loss
China: Increase in revenue and profit due to cost reduction
Hard Backlog by Region
* Hard backlog:
The balance of the amount for orders for contract business already concluded. This is an indicator that shows the amount of sales to be generated over the next one to five years and serves as the basis for the group's future results forecasts.
(Millions of yen)
4,191
2,242
4,242
4,378
10,622
11,797
10,898
12,702
11,737
2,188
1,948
1,437
2,892
4,350
2,212
2,756
2,578
4,765
3,192
2,705
2,422
1,790
2,031
3,387
2,043
15,000
10,000
5,000
AsiaEU
US
Japan
0
2025/3 2025/6 2025/9 2025/12 2026/2/13
The hard backlog as of February 13, 2026 was 12.7 billion yen, up 8.2% from the end of March 2025